Most recently reported pay: $9.3M. No year-by-year proxy breakdown is on file — common for foreign private issuers and recently listed companies, which do not file a US proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
Sep 15, 2026https://www.marketbeat.com/instant-alerts/event-sarepta-sees-elevidys-demand-stabilizing-as-fshd-dm1-readouts-near-2026-09-15/sentiment -0.50
Novartis: 2 Significant Pipeline Setbacks Can Be Absorbed
Sep 8, 2026https://seekingalpha.com/article/4943818-novartis-two-significant-pipeline-setbacks-can-be-absorbedsentiment -0.20
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
Sep 7, 2026https://www.zacks.com/stock/news/2985908/amgen-shares-fall-as-novartis-pelacarsen-misses-phase-iii-study-goal?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2985908sentiment -0.80
BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off
Sep 5, 2026https://seekingalpha.com/article/4943348-bioage-cv-risk-data-due-h2-a-major-catalyst-after-rivals-data-causes-sell-offsentiment +0.10
Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports
Sep 1, 2026https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-pauses-autoimmune-cell-therapy-studies-after-deaths-wsj-reports-2026-09-01/sentiment -0.80
VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
Aug 23, 2026https://www.marketbeat.com/articles/vig-vym-and-vymi-which-vanguard-dividend-etf-is-right-for-you/sentiment +0.10
